Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review
Open Access
- 9 November 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 103 (12), 1858-1869
- https://doi.org/10.1038/sj.bjc.6605984
Abstract
Recent decades have seen combination chemoradiotherapy become the standard treatment for anal squamous cell carcinoma (SCC). However, the burden of this disease continues to rise, with only 10% of patients with metastatic disease surviving >2 years. Further insight into tumour characteristics and molecular biology may identify novel therapeutic targets. This systematic review examines current prognostic markers in SCC of the anus. An extensive literature search was performed to identify studies reporting on biomarkers in anal cancer in the context of clinical outcome following treatment primarily with chemoradiotherapy. In all, 21 studies were included. A total of 29 biomarkers were studied belonging to 9 different functional classes. Of these biomarkers, 13 were found to have an association with outcome in at least one study. The tumour-suppressor genes p53 and p21 were the only markers shown to be of prognostic value in more than one study. An array of biomarkers have been identified that correlate with survival following chemoradiotherapy in anal cancer. However, investigators are yet to identify a biomarker that has the ability to consistently predict outcome in this disease. Further studies are needed to elucidate whether these candidate biomarkers demonstrate their optimum value when they serve as targets for new therapeutic strategies.Keywords
This publication has 92 references indexed in Scilit:
- Human Papillomavirus and Survival of Patients with Oropharyngeal CancerThe New England Journal of Medicine, 2010
- Molecular targeted therapies in head and neck cancer - An update of recent developements -Head & Neck Oncology, 2010
- Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalThe Lancet Oncology, 2010
- PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancerBritish Journal of Cancer, 2009
- K-ras status in squamous cell anal carcinoma (SCC): it’s time for target-oriented treatment?Cancer Chemotherapy and Pharmacology, 2009
- Is NF-κB a good target for cancer therapy? Hopes and pitfallsNature Reviews Drug Discovery, 2009
- Activation of the retinoblastoma tumor suppressor mediates cell cycle inhibition and cell death in specific cervical cancer cell linesMolecular Carcinogenesis, 2008
- Gene expression reveals two distinct groups of anal carcinomas with clinical implicationsBritish Journal of Cancer, 2008
- NF-κB and cancer—identifying targets and mechanismsCurrent Opinion in Genetics & Development, 2008
- Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical TrialJNCI Journal of the National Cancer Institute, 2008